Presentation is loading. Please wait.

Presentation is loading. Please wait.

Optimisation of therapy in Gram-negative infections: TEMOCILLIN

Published byAshley Ross Modified over 6 years ago

Similar presentations

Presentation on theme: "Optimisation of therapy in Gram-negative infections: TEMOCILLIN"— Presentation transcript:

1 Optimisation of therapy in Gram-negative infections: TEMOCILLIN
ESCMID Conference on Reviving Old Antibiotics Optimisation of therapy in Gram-negative infections: TEMOCILLIN Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgium < 22/10/2014 ESCMID - temocillin

2 In a nutshell … Temocillin identity card
Name: temocillin ; 6--methoxy-ticarcillin Passport number: ATC code J01CA17 Birthdate: 1984 Birthplace: Beecham company, London, UK Current address: Eumedica, Manage, Belgium VISA: registered in Belgium; Luxembourg, UK Current position: IV/IM – infections by Gram(-) bacteria empirical treatment: complicated urinary tract infections documented treatment: lower respiratory tract infections wound infections bacteraemia orphan drug designation: Burkholderia cepacia infection in cystic fibrosis patients SPC, last revision 2012 22/10/2014 ESCMID - temocillin

3 Spectrum of activity Susceptible organisms MIC < 1 mg/L
1 mg/L < MIC < 10 mg/L 10 mg/L < MIC < 100 mg/L Moraxella catarrhalis Haemophilus influenzae Legionella pneumophila Neisseria gonorrhoeae Neisseria meningitidis Brucella abortus Citrobacter spp. Escherichia coli Klebsiella pneumoniae Pasteurella multocida Proteus mirabilis Proteus spp (indole +) Providencia stuartii Salmonella Typhimurium Shigella sonnei Yersinia enterocolitica Serratia marcescens Enterobacter spp Intrinsically resistant organisms anaerobes Gram(+) bacteria Acinetobacter spp Pseudomonas aeruginosa ESKAPE pathogens SPC, last revision 2012; Van Landuyt et al, AAC 1982; 22:535-40 22/10/2014 ESCMID - temocillin

4 What about ESBL/carbapenemase producers ?
NDM VIM IMP OXA-48 hydrolysis TEM SHV CTX-M KPC most OXA NO hydrolysis β-lactamase temocillin Know your local epidemiology ! Matagne et al, Biochem J 1993; 293:607-11; Livermore et al, Int J Antimicrob Agents. 2011; 37:415-9 22/10/2014 ESCMID - temocillin

5 What about ESBL/carbapenemases producers ?
Temocillin MIC distribution for ESBL and AmpC overproducers (E. coli, Klebiella spp, Enterobacter spp, Citrobacter spp, Serratia spp) MIC90 MIC50 Adapted from Livermore et al, JAC 2006; 57:1012-4 22/10/2014 ESCMID - temocillin

6 PK and dosage Protein binding ~ 85 % Creat. Clearance dose Cmax (1 g)
Estimated Cmin (1 g) Normal 1-2 g q12h 173 mg/L 4.2 h ~ 22 mg/L > 60 ml/min 30-60 ml/min 1 g q12h 120 mg/L 20 h ~ 80 mg/L 10-30 ml/min 1 g q24h 118 mg/L 17 h < 10 ml/min 0.5-1 g q24-48h 28 h hemodialysis 1 g after dialysis 0.5 g if 24 h Protein binding ~ 85 % SPC, last revision 2012 22/10/2014 ESCMID - temocillin

7 What does temocillin bring to the pharmacologist ?
Pharmacy Barmherzige Brüder Vienna 22/10/2014 ESCMID - temocillin

8 Dosage: PK/PD to the rescue
ICU patients 2 g q12 h PK/PD Bkpt 8-16 mg/L BSAC Bkpt: ≤ 8 mg/L (systemic) ≤ 32 mg/L (urinary) Monte Carlo simulation MIC90 PK/PD target MIC90 LD: 2 g; CI 4g/24h MIC90 De Jongh et al, JAC 2008; 61:382-8 22/10/2014 ESCMID - temocillin

9 Dosage: PK/PD to the rescue
ICU patients 2 g q8 h PK/PD Bkpt 8-32 mg/L BSAC Bkpt: ≤ 8 mg/L (systemic) ≤ 32 mg/L (urinary) MIC90 Monte Carlo simulation PK/PD target MIC90 LD: 2 g; CI 6g/24h MIC90 Laterre et al, JAC [accepted] 22/10/2014 ESCMID - temocillin

10 Dosage: PK/PD to the rescue
continuous veno-venous hemofiltration hemodialysis LD: 0.75 g; CI 0.75g/24h 2 g/48 h (post-dialysis) MIC90 MIC90 Laterre et al, JAC [in revision]; Miranda Bastos et al, ESCMID old antibiotics 2014; P26 22/10/2014 ESCMID - temocillin

11 What does temocillin bring to the microbiologist?
Tree of life by Gustav Klimt in 1909. 22/10/2014 ESCMID - temocillin

12 Rapid screening test for carbapenemase
Huang et al, JAC 2014; 69:445-50 22/10/2014 ESCMID - temocillin

13 What does temocillin bring to the clinician ?
Hygeia - detail from “Medicine,” the second of the University of Vienna’s three commissioned works by Gustav Klimt from 22/10/2014 ESCMID - temocillin

14 What does temocillin bring in our arsenal ?
(1) Targeted spectrum  sparing of broad spectrum drugs Glupczynski et al, Eur J Clin Microbiol Infect Dis 2007; 26:777–83 22/10/2014 ESCMID - temocillin

15 What does temocillin bring in our arsenal ?
(1) Targeted spectrum  sparing of broad spectrum drugs Efficacy in HAP GI adverse effects Habayeb, FIS 2013 and ECCMID 2013; O273 22/10/2014 ESCMID - temocillin

16 What does temocillin bring in our arsenal ?
(2) Targeted spectrum  sparing of broad spectrum drugs lack of cross resistance Resistance rates in E. coli from transrectal prostate biopsy Clinical interest Steensels et al, CMI 2012; 18: 575–81 Balakrishnan & Smith; JAC 2013;68:2418-9 22/10/2014 ESCMID - temocillin

17 What does temocillin bring in our arsenal ?
(2) Targeted spectrum  sparing of broad spectrum drugs lack of cross resistance Clinical efficacy against N. gonorrheae Susceptibility of recent isolates (n=76) CIP R : % Pen I+R : 71 % CRO R: 0 % median TEM MIC: 0.75 mg/L (10-90%: mg/L) Reimer et al, Drugs 1985; 29S5:210-2 Ghathian et al, ECCMID 2013; O314 22/10/2014 ESCMID - temocillin

18 What does temocillin bring in our arsenal ?
(3) Chemical stability  Outpatient Parenteral Antibiotic Therapy B. cepacia infections in CF patients Resistant urinary tract infections Dube & Iqbal, FIS 2013 adapted from Carryn et al, JAC 2010; 65:2045-6 22/10/2014 ESCMID - temocillin

19 What does temocillin bring in our arsenal ?
(4) Salvage therapy for MDR Burkholderia spp 22/10/2014 ESCMID - temocillin

20 What about Pseudomonas aeruginosa ?
Temocillin vs ticarcillin MIC distribution for P. aeruginosa collected from CF patients (n= 335) OprM MexA Strain/genotype MIC (mg/L) PAO1 256 PAO1 ΔmexAB-oprM 4 CF strain; deletion in mexB 1 CF strain; deletion in mexA 2 CF strain; mutation in mexA 32 MexB ? efflux non functional ! Buyck et al, JAC 2012; 67:771-5; Chalhoub et al, ESCMID old antibiotics 2014, P02 22/10/2014 ESCMID - temocillin

21 Take home message 22/10/2014 ESCMID - temocillin

22 Temocillin PROS and CONS
Safety profile Active on most ESBL-producers Limited spectrum Prolonged half-life Stability for C.I. Inactive if carbapenemase/OXA-48 Combination needed if polymicrobial infection High doses required 22/10/2014 ESCMID - temocillin

23 Perspective for future research
22/10/2014 ESCMID - temocillin

24 Perspective for future research
Definition of PK/PD breakpoint Any specific mechanism of resistance beside carbapenemases ? PK in specific populations (paediatrics, e.g.) Further documentation of clinical efficacy for currently off-label indications 22/10/2014 ESCMID - temocillin

Download ppt "Optimisation of therapy in Gram-negative infections: TEMOCILLIN"

Similar presentations

Pharmacodynamics and the Dosing of Antibacterials

Pharmacodynamics and the Dosing of Antibacterials
Emerging Antimicrobial Resistance in Texas The new ESBLs.

Emerging Antimicrobial Resistance in Texas The new ESBLs.
 Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized.

 Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized.
Enoch Omonge University of Nairobi

Enoch Omonge University of Nairobi
Lecture 5 Enzymatic destruction (ESBL) Enzymatic modification (erm )

Lecture 5 Enzymatic destruction (ESBL) Enzymatic modification (erm )
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.

25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
Methods Revised Abstract Methods Results TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory.

Methods Revised Abstract Methods Results TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory.
Beta lactam antibiotics & Other cell wall synthesis inhibitors

Beta lactam antibiotics & Other cell wall synthesis inhibitors
BSAC User Group Meeting 2007 BSAC recommendations for interpreting the susceptibility of urinary tract isolates Jenny Andrews.

BSAC User Group Meeting 2007 BSAC recommendations for interpreting the susceptibility of urinary tract isolates Jenny Andrews.
Adham Abu Taha, PhD Dept. of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine Antimicrobial resistance.

Adham Abu Taha, PhD Dept. of Pharmacology and Toxicology, College of Pharmacy, An-Najah National University, Nablus, Palestine Antimicrobial resistance.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.

8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Quinolone and Aminoglycoside Antibiotics Edgar Rios, Pharm.D., BCPS MHH Clinical Pharmacist UTHSCH Clinical Assistant Professor.

Quinolone and Aminoglycoside Antibiotics Edgar Rios, Pharm.D., BCPS MHH Clinical Pharmacist UTHSCH Clinical Assistant Professor.
Introduction: Temocillin (TMO) is a narrow spectrum penicillin with good activity against Gram negative micro-organisms including ESBL and AmpC producers.

Introduction: Temocillin (TMO) is a narrow spectrum penicillin with good activity against Gram negative micro-organisms including ESBL and AmpC producers.
Points for Discussion Anti-Infective Drugs Advisory Committee Meeting March 5, 2003.

Points for Discussion Anti-Infective Drugs Advisory Committee Meeting March 5, 2003.
Pk/Pd modelling : Clinical Implications

Pk/Pd modelling : Clinical Implications
Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.

Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.
Operations  Started research operations (10 FTEs) in September 2011  Redx Anti-Infectives launched in Alderley Park in April 2013  Currently 55 scientists.

Operations  Started research operations (10 FTEs) in September 2011  Redx Anti-Infectives launched in Alderley Park in April 2013  Currently 55 scientists.
Background and Objectives Methods

Background and Objectives Methods
Bacterial persistence

Bacterial persistence
A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.

A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.

Similar presentations

Ads by Google